Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538559 | 0.85 | PTGS2 (0.46) | PTGS2PTGS1MMP1MMP2MMP3 | |
| SCHEMBL7540175 | 0.85 | PTGS2 (0.50) | PTGS2PTGS1MMP1MMP2MMP3 | |
| SCHEMBL7542568 | 0.85 | PTGS2 (0.49) | PTGS2PTGS1MMP1MMP2MMP3 | |
| SCHEMBL7543918 | 0.82 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL7541544 | 0.78 | PTGS2 (0.66) | PTGS2PTGS1MMP1MMP2MMP9 | |
| SCHEMBL7046074 | 0.72 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL6718766 | 0.72 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5071852 | 0.72 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL8870727 | 0.71 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL6723207 | 0.71 | PTGS2 (0.44) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885MMP1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.